April 18 (Reuters) - Telesta Therapeutics Inc TST.TO
* Telesta announces type a meeting results and strategic
option review
* Co's questions for meeting were centered on whether fda
would permit co to resubmit bla for mcna 1 under accelerated
approval
* Fda has ruled any potential commercial approval of mcna to
require an additional phase 3 clinical trial to be completed
* Telesta currently estimates that u.s. Regulatory approval
for mcna could not be obtained for a period of at least 5 years
* Telesta has determined that it will not pursue another
phase 3 clinical trial on its own
* Company will seek a partner for future development of mcna
in u.s.
* Working with board of directors to identify strategic
options
* Strategic option review includes sale and/or merger of
company, sale and/or licensing of assets
* Continue to review and will implement additional cost
reduction
Source text for Eikon: ID:nPn73y4zKa
Further company coverage: TST.TO
(Bengaluru Newsroom: +1-646-223-8780)